Novo Nordisk honored by National Hemophilia Foundation

PRINCETON, N.J. — Danish drug maker Novo Nordisk has received the Corporate Leadership Award from the National Hemophilia Foundation in response to its research and development efforts for the disease, the company said Friday.

“We are honored by this recognition and are pleased to support NHF in its continued efforts to build a national movement toward better patient care in hemophilia,” Novo Nordisk corporate VP biopharmaceuticals Eddie Williams said. “We look forward to many more years of continued research, innovative treatments and initiatives to help improve the lives of patients.”

The company said it was dedicated to making advancements in strengthening the understanding of hemophilia in the broader society, improving access to diagnosis and patient care, and advancing treatment through innovation. It also supports SevenSecure, a program that offers access to financial, educational and medical support and provides funding for the Inhibitor Education Summits, designed for people living with hemophilia.

Hi-Tech granted tentative approval for generic Levaquin

AMITYVILLE, N.Y. — The Food and Drug Administration has granted tentative approval to a generic antibiotic made by Hi-Tech Pharmacal, the drug maker said Friday.

Hi-Tech announced the tentative approval of levofloxacin oral solution in the 25 mg-per-mL strength. The drug is used to treat mild, moderate and severe bacterial infections in adults.

Levofloxacin oral solution is a generic version of Johnson & Johnson’s Levaquin. Levaquin had sales of $6 million in 2010, according to IMS Health. Levaquin expects to receive final approval in June, when Johnson & Johnson’s patent expires.

Impax, Banner to develop two softgel capsule products

HAYWARD, Calif., and HIGH POINT, N.C. — Impax Labs will collaborate with a specialty pharmaceutical company dedicated to the research, development and manufacturing of unique gelatin-based dosage forms.

Impax said it has entered a deal with Banner Pharmacaps in respect to the supply and commercialization of two softgel capsule products.

RELATED NEWS

The Food and Drug Administration has approved a generic of Hoffman-La Roche’s Tamiflu (oseltamivir phosphate) capsules from Lupin. The company’s generic will be available in 30-, 45- and 75-mg dosage strengths.
The product is inficated to treat acute, uncomplicated influenza A and B in patients 2 weeks of age and older, as well as to prevent influenza A and B in patients 1 year old and older. The drug had U.S. sales of roughly $467.8 million for the 12 months ended October 2017, according to IQVIA data.

Behavioral health pharmacy and telepsychiatry company Genoa, a QoL Healthcare Company, has reached a big number with its remote psychiatry offering. The Tukwila, Wash.-based company announced Tuesday that it had facilitated more than 100,000 telepsych consultations on its video conferencing platform.
Genoa attributes the milestone to its recent buildup of its telepsychiatry operations, which grew to include 35 in 2017 from 20 at the start of the year, and included 250 providers. In 2017, the company grew to serve more than 2,500 patients per week.

This year's flu continues to be Texas big, according to the Walgreens Flu Index released Wednesday, as the top 10 communities experiencing the greatest amount of flu incidence were all located in the Lone Star State for the week ended Jan. 6.
Iowa, Idaho and Arkansas rank behind Texas in terms of flu activity. And Montana, Idaho and Iowa ranked highest among states experiencing flu activity gains.

Amneal Biosciences has launched its generic of Otsuka’s Busulfex (busulfan injection, 6 mg/ml). The product is indicated to treat chronic myelogenous leukemia.
Amneal said that its generic is available in cartons of eight single-dose vials, each of which contains 60 mg of the drug in a 10-ml clear sterile solution. The product is made without natural rubber, latex, gluten or preservatives, Amneal said.
The drug had U.S. sales of roughly $80 million for the 12 months ended October 2017, according to data from IQVIA.

Amneal Pharmaceuticals has launched sevelamer carbonate tablets, 800 mg, in 270-count bottles. This generic from the Bridgewater, N.J.-based company is an AB-rated therapeutic equivalent to Renvela.
Amneal also launched five other products in addition to sevelamer carbonate:

Forgotten Password

Registration complete

REGISTER

USERNAME *

Spaces are allowed; punctuation is not allowed except for periods, hyphens, and underscores.

E-MAIL ADDRESS *

A valid e-mail address. All e-mails from the system will be sent to this address. The e-mail address is not made public and will only be used if you wish to receive a new password or wish to receive certain news or notifications by e-mail.

Password *

Confirm Password *

Please choose a password for your account; it must be 8 - 30 characters. .

First Name *

Last Name *

Company Name *

Job Title *

ZIP *

Are you a *

Retailer or Healthcare professional

Non-Retailer

How many stores do you operate?: *

Which best describes the business/industry you work in?: *

Which best describes your job title?: *

Please select the newsletters you would like to subscribe to

DSN A.M.
Daily news stories covering the retail drug industry

Breaking News
First-to-the-market with developing stories in the industry